Table 6.
Logistic regression model with significant methotrexate and corticoid candidate genes
| Extreme phenotype | Dyslipidemia | ||||
|---|---|---|---|---|---|
| BAD/rs2286615 (C, DOM, ADD) | BAD (CR) | APOB/rs676210 (C, DOM) | BAD/rs2286615 (C, ADD) | BAD (CR) | |
| OR (95% CI) p-value |
|||||
| Age | 1.219 (1.005-1.478) | 1.213 (1.017-1.447) | 1.041 (0.971-1.117) | 1.047 (0.961-1.141) | 1.037 (0.966-1.114) |
| 0.044 | 0.032 | 0.259 | 0.292 | 0.313 | |
| Gender | 1.152 (0.216-6.142) | 1.624 (0.340-7.749) | 0.726 (0.365-1.444) | 1.058 (0.453-2.472) | 1.043 (0.506-2.151) |
| 0.869 | 0.543 | 0.361 | 0.896 | 0.908 | |
| Corticoid | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) |
| 0.577 | 0.355 | 0.411 | 0.519 | 0.571 | |
| Asparaginase | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) |
| 0.714 | 0.444 | 0.372 | 0.704 | 0.344 | |
| Methotrexate | 0.999 (0.999-1.000) | 0.999 (0.999-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) |
| 0.075 | 0.048 | 0.783 | 0.225 | 0.642 | |
| CRT | 14.506 (1.116-188.530) | 16.098 (1.220-212.463) | 1.572 (0.619-3.994) | 2.361 (0.751-7.425) | 2.255 (0.843-6.033) |
| 0.041 | 0.035 | 0.341 | 0.142 | 0.105 | |
| Energy balance | 0.999 (0.998-1.001) | 1.000 (0.998-1.001) | 1.000 (0.999-1.000) | 1.000 (0.999-1.000) | 1.000 (0.999-1.000) |
| 0.297 | 0.421 | 0.469 | 0.319 | 0.350 | |
| Med score | 0.652 (0.319-1.329) | 0.752 (0.374-1.513) | 1.017 (0.813-1.272) | 1.029 (0.793-1.334) | 0.984 (0.780-1.240) |
| 0.239 | 0.425 | 0.885 | 0.831 | 0.888 | |
| SNP | 57.900 (3.152-1063.462) | 69.819 (4.202-1159.995) | 0.434 (0.215-0.877) | 4.022 (1.441-11.226) | 3.560 (1.427-8.882) |
| 0.006 | 0.003 | 0.020 | 0.008 | 0.006 | |
| Obesity | Pre-hypertension | Insulin resistance | |||
| BAD/rs2286615 (C, DOM) |
BAD/rs2286615 (C, ADD) |
CRHR1
(R) |
CRHR2
(R) |
SERPINA6/rs2228541 (C, ADD) | |
| OR (95% CI) p-value |
|||||
| Age | 0.996 (0.914-1.085) | 0.998 (0.916-1.087) | 1.010 (0.873-1.169) | 0.995 (0.869-1.139) | 1.085 (0.993-1.185) |
| 0.926 | 0.959 | 0.896 | 0.940 | 0.073 | |
| Gender | 1.979 (0.824-4.750) | 2.073 (0.854-5.034) | 0.081 (0.009-0.741) | 0.165 (0.033-0.809) | 1.330 (0.562-3.150) |
| 0.127 | 0.107 | 0.026 | 0.026 | 0.517 | |
| Corticoid | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) |
| 0.998 | 0.971 | 0.828 | 0.830 | 0.898 | |
| Asparaginase | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) |
| 0.863 | 0.824 | 0.621 | 0.452 | 0.141 | |
| Methotrexate | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (0.999-1.000) | 1.000 (0.999-1.000) | 1.000 (1.000-1.000) |
| 0.825 | 0.786 | 0.160 | 0.364 | 0.935 | |
| CRT | 1.915 (0.607-6.038) | 2.029 (0.636-6.480) | 7.685 (0.713-82.885) | 3.558 (0.550-23.009) | 1.539 (0.463-5.118) |
| 0.267 | 0.232 | 0.093 | 0.183 | 0.482 | |
| Energy balance | 1.000 (0.999-1.000) | 1.000 (0.999-1.000) | 1.000 (0.999-1.001) | 0.999 (0.998-1.000) | 1.000 (0.999-1.000) |
| 0.137 | 0.153 | 0.573 | 0.168 | 0.257 | |
| Med score | 0.921 (0.710-1.195) | 0.911 (0.700-1.184) | 0.871 (0.562-1.349) | 0.806 (0.555-1.170) | 0.939 (0.713-1.236) |
| 0.534 | 0.485 | 0.536 | 0.257 | 0.652 | |
| SNP | 3.993 (1.410-11.307) | 4.044 (1.504-10.879) | 76.406 (0.948-6158.616) | 3.417 (0.384-30.405) | 0.534 (0.286-0.998) |
| 0.009 | 0.006 | 0.053 | 0.271 | 0.049 | |
Top: Odds ratio (95% CI), bottom: p-value
Boldface: Significant association
C common, CR common/rare, R rare, DOM Dominant effect, ADD Additive effect, CRT Cranial radiotherapy, Med score Mediterranean diet score, Extreme phenotype Three and more cardiometabolic risk factor